💸 The Tape

Cronos Group (NASDAQ: CRON / TSX: CRON) has put a stake in the ground in one of cannabis's most contested categories. The company confirmed that its Spinach® vape portfolio is now the top-selling vape brand in Canada, capturing 10.4% of the total vape category in April 2026 on HiFyre data — and, more tellingly, that it has held the #1 position since January 2026. In a market where leaderboards turn over quarterly and "momentum" is usually a euphemism for a single good month, four consecutive months at the top is a durability signal, not a flash in the pan.

The win matters because of where it happened. Vapes now account for roughly a third of the Canadian recreational market, running neck-and-neck with pre-rolls and pulling away from a structurally declining flower category. It's also concentrated — the top five players control well over half of the category — which makes share leadership a genuine moat rather than a vanity stat. Cronos built its position on a quality-and-technology pitch: high-purity extracts, distinctive terpene profiles, and hardware engineered for consistent performance. Chief Growth Officer Jeff Jacobson framed the #1 spot as validation of that formula, and the company isn't easing off — a summer slate of new SKUs is on deck, including three new Spinach PUFFERZ™ all-in-one flavors (Strawberry Burst, Peach Iced Tea, Grape Gas) and the brand's first-ever limited-time-offer vape, an Orange Vanilla Twist cartridge, all infused with liquid diamonds for bigger, smoother hits. The new drops hit Alberta and Ontario in late June, with national availability to follow.

The more interesting story sits underneath the percentage. Cronos didn't back into the top spot in a sleepy category — it took it from Organigram, which had vaulted into the #1 vape position via its 2024 acquisition of Motif and the BOXHOT brand. That's the competitive tell worth sitting with: the company perpetually dismissed as "a balance sheet in search of a business" out-executed a peer that bought its way to the lead, and has held the line for four straight months against that pressure, plus Tilray's Good Supply and Redecan portfolio and Decibel's General Admission. Spinach won on product, not on a checkbook — which says something about whether the brand engine can compound.

CEO Mike Gorenstein tied the vape result to a bigger idea, describing Cronos's strategy as building "disruptive, borderless products that can scale as regulations evolve globally." That phrasing isn't throwaway. It's the connective tissue between the Canadian win and the question every CRON investor actually cares about: what happens when the U.S. opens up, and what does Cronos do with its cash.

Cronos has the rarest problem in cannabis: too much cash and not enough sanctioned places to deploy it. The company closed Q1 2026 with roughly $822 million in cash and equivalents and zero debt, a position that traces back to Altria's ~$1.8 billion strategic investment in 2019 and has been guarded with near-religious discipline ever since. The balance sheet is so liquid that interest income of roughly $9.7 million for the quarter outran the operating business itself — Cronos is, quite literally, being paid to wait. Management also renewed a $50 million buyback, repurchasing about $16.7 million of stock in the quarter, which in this sector still qualifies as a flex.

So the M&A question writes itself: if full U.S. rescheduling arrives, does that $822 million become the most potent acquisition currency in the industry? The honest answer requires a nuance worth saying out loud. Major exchanges are listing medical only cannabis companies which are now federally compliant via the DEA. It eliminates the punitive 280E tax burden and reshapes the research and pharmaceutical calculus, but it does not legalize interstate commerce or resolve the exchange-listing and banking exposure that has kept Cronos at arm's length from American flower. The real unlock is federal normalization that permits interstate commerce — which is precisely the scenario Gorenstein's "borderless products" language is built for.

If that fuller unlock lands, Cronos is arguably the best-positioned acquirer in the space. It can write a meaningful check without touching the debt markets that have hollowed out its peers; it has a strategic partner in Altria with distribution muscle and regulatory patience; and its platform is purpose-built to carry proven brands — Spinach vapes being exhibit A — across borders. The likeliest playbook isn't a transformational MSO takeout; it's opportunistic acquisition of brands, IP, and category-leading assets at distressed valuations, the move a clean balance sheet enables when everyone else is a forced seller. The risk, as always, is that "optionality" becomes a permanent state — the market has waited years for Cronos to deploy.

Beneath the cash narrative, the business is performing better than the bears allow. Q1 2026 net revenue rose 40% year-over-year to a record $45.2 million. Canadian retail sales grew roughly 18%, with Cronos holding genuine category leadership beyond vapes — edibles share near 20.8%, gummies around 22.7%. Supply from the Cronos GrowCo expansion is fueling the next leg, though management candidly flagged flower supply constraints as a governor on share gains in that specific category. The international engine is arguably stronger still: Cronos Israel posted its ninth consecutive record quarter, up ~53%, with PEACE NATURALS the country's #1 brand, while international revenue overall jumped ~97%, driven by Germany's medical market.

The Spinach vape win is more than a press release — it's evidence that Cronos's product machine can take and hold share against well-capitalized competition. But the equity thesis still ultimately rests on what management does with $822 million when the U.S. door swings fully open. For now, Cronos is the sector's coiled spring: executing in Canada, compounding abroad, and sitting on the firepower to move decisively the moment the catalyst everyone is waiting on finally arrives. Discipline has kept it alive. Deployment is what will define it.

📈 Dog Walkers

$VRNO ( ▲ 0.17% ) Executes Split

Verano Holdings has completed its 1-for-5 reverse stock split, effective today — another domino falling in the cannabis industry's march toward major exchange listings.

The consolidation reduces Verano's outstanding common shares from approximately 367.7 million to 73.9 million, while authorized shares drop from 5 billion to 1 billion. The move builds on the company's November 2025 redomiciliation from British Columbia to Nevada and is explicitly designed to position for a future U.S. exchange uplisting.

Shares continue trading on Cboe Canada under "VRNO" and will trade on the OTCQX under "VRNOD" for the next 20 business days before reverting to the original symbol. The company's Normal Course Issuer Bid has been amended to reflect the new share count, with up to 3.6 million post-split shares available for repurchase.

Verano is now the third major MSO to execute a reverse split in recent weeks, following Curaleaf's 1-for-3 and Trulieve's deconsolidation and NYSE listing. With 162 dispensaries across 13 states, nearly $50 million in quarterly adjusted EBITDA, and a freshly restructured balance sheet, Verano is making clear it intends to be next in line when the exchange door opens wider.

$GLASF ( ▼ 0.08% ) Files Shelf Prospectus

Glass House Brands just doubled the size of its capital markets toolkit — and notably, hasn't used the first one yet.

The company filed a new short form base shelf prospectus replacing its expiring prior shelf, along with an updated at-the-market (ATM) distribution program allowing the sale of up to US$100 million in equity shares through ATB Cormark Capital Markets. That's double the $50 million ATM announced just weeks ago — under which, the company disclosed, no equity sales occurred.

The fact that Glass House filed a larger ATM without having sold a single share under the previous program sends a mixed signal. On one hand, management describes it as a "long-term source of potential capital to be accessed on an opportunistic basis" for cultivation expansion, acquisitions, and general corporate purposes. On the other, a company running negative adjusted EBITDA and negative operating cash flow in Q1 while doubling its dilution capacity raises legitimate questions about future capital needs.

Glass House is targeting one million pounds of annual biomass production and has reiterated its $95 per pound cost target for the second half of 2026. If those targets materialize, the ATM may never be needed. If they don't, having $100 million in available equity issuance provides a safety net — one that existing shareholders will be watching closely.

🗞️ The News

📺 Trade To Black

Big Changes Are Hitting The Cannabis Industry Now | TTB Presented by Flowhub

• Stay Motion Filed: SAM, NDASA, and MMJ International have asked the D.C. Circuit to freeze the Schedule III rescheduling order and revert cannabis to Schedule I while the consolidated lawsuits proceed — arguing Acting AG Todd Blanche bypassed required DEA hearing and formal rulemaking procedures.

• LEEF Brands California Thesis: Board member Jamie Mendola makes the case for why scale in California can still be a strategic advantage despite the state's notorious pricing and regulatory challenges.

• FundCanna x Apex Trading: CEO Adam Stettner announces FundCanna's integration of ReadyPaid BNPL directly into Apex Trading's $150M monthly marketplace — a move that could fundamentally change how capital flows through cannabis wholesale transactions.

• The Big Question: The rescheduling stay motion forces the industry to confront whether the procedural shortcut the government used to reach Schedule III can survive legal scrutiny — with Trulieve's NYSE listing, 280E relief, and hundreds of DEA registrations potentially hanging in the balance.